March 7, 2007 -- Avalon will collaborate with Merck to develop a new cancer treatment in a deal that could top $200 million in milestones; CV Therapeutics said Ranexa failed a Phase III trial in patients with acute coronary syndrome; Insmed settled its patent dispute with Tercica and Genentech over a short-stature drug; Compugen extended its agreement with Biosite to develop biomarkers; the FDA will not require ZymoGenetics to conduct a Phase III trial of its recombinant human thrombin spray product for approval; and Encysive won approval in Australia for Thelin in patients with pulmonary arterial hypertension. The Centient Biotech 200™ dropped 17 points to end at 3817, a loss of .44%. More details...
